Naveen Gupta joins LambdaTest as its Chief Financial Officer
6.4.2023 15:30:00 EEST | Business Wire | Press release
LambdaTest, an intelligent omnichannel digital experience testing cloud platform, has announced the appointment of Naveen Gupta as its Chief Financial Officer. He comes with more than 35 years of experience across industries and brings a wealth of financial and strategic experience to LambdaTest, having held several executive roles at prominent companies in the past.
In his new role at LambdaTest, Naveen will lead the finance and accounting functions, helping to drive the company's growth and profitability. He will be responsible for financial planning, revenue projections, profit, business growth objectives, and risk management, among other responsibilities.
Naveen was most recently the CFO at Innovaccer, a Silicon Valley-based digital healthcare company. He was previously with Thomson Reuters, Pangea3 (acquired by Thomson Reuters), GlobalLogic India, and Xansa among other companies.
“Naveen comes with deep strategic expertise in scaling finance functions at technology companies and would be an invaluable asset for us. His three-and-a-half decades track record speaks for itself. Naveen will be our guiding light when it comes to growth and profitability. We are excited to welcome him to the LambdaTest rocketship,” said Asad Khan, CEO, LambdaTest.
“The innovation that LambdaTest is doing to disrupt the digital experience testing landscape excited me. The potential that such core innovation has is immense. Additionally, LambdaTest’s deep focus on partnerships to enable an integrated enterprise execution environment will fundamentally change the siloed approach to testing and will give companies a unified and streamlined experience,” said Naveen Gupta, CFO, LambdaTest. “The company leadership’s vision on productivity and efficiency is deep-rooted and my task is to carry forward the baton and strategically move towards growth and profitability. I’m looking forward to this journey.”
LambdaTest also recently announced the launch of its digital experience testing cloud for enterprises. The offering will enable enterprises to accelerate their digital transformation by providing a best-in-class, 360-degree test execution and orchestration platform coupled with insightful test analytics and customizable deployment options–public cloud, single tenant, or on-premise.
About LambdaTest
LambdaTest is an intelligent unified digital experience testing cloud that helps businesses drastically reduce time to market through faster test execution, ensuring quality releases and accelerated digital transformation. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
Continuous Testing Cloud
LambdaTest's Continuous Testing Cloud allows enterprises to rapidly test and deploy changes to their web and mobile applications up to 70% faster, which helps to accelerate the development process and improve time-to-market.
Cross-browser Testing Cloud
Our cross-browser testing cloud allows users to test their websites and web applications on a wide variety of browsers, operating systems, and devices. With features such as real-time testing, responsive design testing, and debugging tools, it enables developers to ensure that their websites and web apps are compatible with different browsers, thereby providing a seamless user experience.
Real Device Cloud
With real device cloud, testers/developers can catch bugs early before their mobile apps go live. With LambdaTest's Real Devices Testing Cloud, teams can test unhandled errors, UI/UX, performance, and functionality of their apps before they get released into production. The teams can also test on the widest range of mobile and OTT devices (iOS, Android, iPad, Amazon Fire TV, Roku TV & Apple TV).
AI-powered Visual Regression Cloud
Ensuring consistent layouts, designs, and functionality of applications is crucial to deliver visually-perfect digital experiences. LambdaTest's visual regression cloud ensures that the visual appearance and functionality of an organization’s web applications remain consistent and error-free, ultimately improving the digital experience and business performance. Teams can get early insights on visual UI bugs before they release their applications to the customer. Testers/developers can run automated visual regression tests on 3000+ combinations of browsers & real devices to identify visual deviations.
AI-powered Integrated Test Intelligence
Test execution insights are critical for digital transformation as they provide enterprises with deeper insight into the quality of releases and trends. By analyzing the test execution data, LambdaTest's integrated test intelligence provides enterprises with insights into patterns and trends that can lead to informed decisions about future development and improve application quality. This can empower development teams with detailed and actionable test execution data and close the gap between data, insight, and action for better and faster decision-making.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005372/en/
Contact information
LambdaTest press office:
press@lambdatest.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release
Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release
For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom